Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended

2023-509981-39-00 Alopecia Areata 4 2024-11-20
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended

2024-510753-10-00 Prurigo Nodularis 5 2024-11-01
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
SPOTLIGHT 204: A Multicenter, Phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability and preliminary efficacy… Ended

2024-511801-51-00 Basal cell carcinoma 4 2024-10-24
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients Ended

2023-509765-20-00 Melanoma: Adjuvant treatment of patients with Stage IIB 2 2024-10-21
Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended

2023-503383-17-01 Female androgenetic alopecia 5 2024-10-10
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No… Ended

2023-510279-80-00 Prurigo nodularis 4 2024-09-25
A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended

2023-503692-24-00 Cutaneous Lupus Erythematosus 5 2024-09-25
Safe Stop ipi-nivo Ended

2024-516938-34-00 Melanoma 5 2024-09-11
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended

2024-511260-84-00 Atopic Dermatitis 4 2024-09-03
Combination therapy of 5-Fluorouracil and Calcipotriol versus 5-Fluorouracil in the treatment of Actinic Keratosis: a multicentre randomized… Ended

2024-511409-42-00 Actinic Keratosis 6 2024-09-02
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination wit… Ended

2023-507377-17-00 Advanced Melanoma 1 2024-08-28
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
DEUCRALIP Ended

2022-502991-21-00 Lichen planus 4 2024-05-22
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended

2023-505782-86-00 Vitiligo 5 2024-04-23
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Vitiligo 5 2024-04-17
INSPIRE (INcreased Sun exposure without Pain In Research subjects with EPP). Ended

2023-506735-15-00 Erythropoietic Protoporphyria or X-Linked Protoporphyri 5 2024-04-05
Vitiligo treatment by targeting TYK2 mediated responses Ended

2023-507451-30-00 Vitiligo 4 2024-04-02